Centromedian thalamic responsive neurostimulation for Lennox-Gastaut epilepsy and autism

Area of Science:

• Neurology
• Pediatric Epilepsy
• Neurostimulation

Background:

• The Responsive Neurostimulation (RNS) System is a recognized treatment for drug-resistant epilepsy.
• Pediatric patients, particularly those with Lennox-Gastaut Syndrome (LGS) and autism spectrum disorder (ASD), have a critical unmet need for effective epilepsy treatments.
• Current treatment options for this population are limited, with surgery often being a last resort.

Purpose of the Study:

• To evaluate the safety and efficacy of the RNS System in pediatric patients with drug-resistant epilepsy secondary to LGS and ASD.
• To explore the potential of RNS System in treating diffuse onset, multifocal epilepsy in children.
• To present case studies demonstrating the impact of RNS System on seizure reduction and quality of life.

Main Methods:

• Two pediatric patients diagnosed with LGS and ASD and drug-resistant epilepsy were treated with the RNS System.
• Treatment involved targeting thalamic networks implicated in LGS seizure generation.
• Clinical seizure reductions were monitored over a follow-up period exceeding one year.

Main Results:

• Both patients experienced significant clinical seizure reductions, ranging from 75% to 99%.
• The RNS System was found to be safe and effective in this pediatric cohort.
• Treatment successfully targeted thalamic networks, avoiding the need for palliative disconnections or resections.

Conclusions:

• Responsive Neurostimulation (RNS) System is a viable and effective treatment option for pediatric patients with drug-resistant epilepsy, LGS, and ASD.
• Targeting thalamic networks with RNS System offers a promising alternative to surgical interventions.
• Further research is warranted to expand the use of RNS System in pediatric epilepsy populations.